The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect.
Parkinson's disease
ambulatory monitoring
digital health
hypokinesia
objective measures
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
08
01
2019
revised:
05
05
2019
accepted:
18
05
2019
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
9
8
2019
Statut:
epublish
Résumé
The BRadykinesia Akinesia INcoordination (BRAIN) tap test is an online keyboard tapping task that has been previously validated to assess upper limb motor function in Parkinson's disease (PD). To develop a new parameter that detects a sequence effect and to reliably distinguish between PD patients The BRAIN test scores in 61 patients with PD and 93 healthy controls were compared. A range of established parameters captured number and accuracy of alternate taps. The new velocity score recorded the intertap speed. Decrement in the velocity score was used as a marker for the sequence effect. In the validation phase, 19 PD patients and 19 controls were tested using different hardware including mobile devices. Quantified slopes from the velocity score demonstrated bradykinesia (sequence effect) in PD patients (slope cut-off -0.002) with 58% sensitivity and 81% specificity (discovery phase of the study) and 65% sensitivity and 88% specificity (validation phase). All BRAIN test parameters differentiated between The BRAIN tap test is a simple, user-friendly, and free-to-use tool for the assessment of upper limb motor dysfunction in PD, which now includes a measure of bradykinesia.
Sections du résumé
BACKGROUND
BACKGROUND
The BRadykinesia Akinesia INcoordination (BRAIN) tap test is an online keyboard tapping task that has been previously validated to assess upper limb motor function in Parkinson's disease (PD).
OBJECTIVES
OBJECTIVE
To develop a new parameter that detects a sequence effect and to reliably distinguish between PD patients
METHODS
METHODS
The BRAIN test scores in 61 patients with PD and 93 healthy controls were compared. A range of established parameters captured number and accuracy of alternate taps. The new velocity score recorded the intertap speed. Decrement in the velocity score was used as a marker for the sequence effect. In the validation phase, 19 PD patients and 19 controls were tested using different hardware including mobile devices.
RESULTS
RESULTS
Quantified slopes from the velocity score demonstrated bradykinesia (sequence effect) in PD patients (slope cut-off -0.002) with 58% sensitivity and 81% specificity (discovery phase of the study) and 65% sensitivity and 88% specificity (validation phase). All BRAIN test parameters differentiated between
CONCLUSION
CONCLUSIONS
The BRAIN tap test is a simple, user-friendly, and free-to-use tool for the assessment of upper limb motor dysfunction in PD, which now includes a measure of bradykinesia.
Identifiants
pubmed: 31392247
doi: 10.1002/mdc3.12798
pii: MDC312798
pmc: PMC6660282
doi:
Types de publication
Journal Article
Langues
eng
Pagination
462-469Subventions
Organisme : Parkinson's UK
ID : F-1201
Pays : United Kingdom
Organisme : Parkinson's UK
ID : G-1606
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Déclaration de conflit d'intérêts
The work presented here had no specific funding, but the Preventive Neurology Unit is funded by the Barts Charity and the Exenatide PD study was funded by the Michael J. Fox Foundation and the Cure Parkinson's Trust. A.J.N. was funded by Parkinson's UK at the time the data were collected and M.B. by the Reta Lila Weston Trust. B.H. and B.J. are directors of uMotif Limited. H.H., M.B., D.S.A., T.W., T.F., G.G., A.J.L., and A.J.N. report no relevant disclosures or conflicts of interest.
Références
J Parkinsons Dis. 2017;7(1):65-77
pubmed: 28222539
Gait Posture. 2013 May;38(1):109-14
pubmed: 23218768
PLoS One. 2014 Apr 29;9(4):e96260
pubmed: 24781810
J Neuroeng Rehabil. 2016 Mar 12;13:24
pubmed: 26969628
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Mov Disord. 2016 Sep;31(9):1283-92
pubmed: 27430969
Mov Disord. 2005 Dec;20(12):1577-84
pubmed: 16116612
Digit Biomark. 2018 Jan 09;1(2):126-135
pubmed: 32095754
Mov Disord. 2005 Oct;20(10):1286-98
pubmed: 16001401
Front Neurosci. 2017 Oct 06;11:555
pubmed: 29056899
J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):31-7
pubmed: 23828833
Lancet. 2017 Oct 7;390(10103):1664-1675
pubmed: 28781108
Mov Disord. 2017 Jan;32(1):80-88
pubmed: 27859579
J Neurol Neurosurg Psychiatry. 1999 Nov;67(5):624-9
pubmed: 10519869
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
NPJ Parkinsons Dis. 2017 Nov 13;3:32
pubmed: 29152558
J Parkinsons Dis. 2016 Jul 2;6(3):631-8
pubmed: 27392872